Related Experiment Video
Updated: Mar 10, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Risk of HIV Escape using Sub-Optimal Antiretroviral Dual or Monotherapy
1Department of Internal Medicine, Puerta de Hierro Research Institute, Majadahonda, Spain.
Abstract:
Budget constrictions have pushed some researchers to explore whether antiretroviral therapy with one or two drugs instead of the well-established triple-drug regimens may be able to maintain undetectable viremia in HIV-infected individuals, at least used as simplification in patients already with viral suppression under standard triple therapy. With the advent of co-formulations and the improved safety of the newest antiretroviral agents, there is no other reason than cost to justify moving from triple to dual or monotherapy.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Viral Mutations
Subviral Agents
Pharmacokinetics in Pediatric Patients: Drug Excretion

